Related Experiment Video
Updated: Jun 8, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Checkpoint inhibitor therapy: Immune-related adverse event management
Lori Davis1, Mary Beth Casselbury, Sharon Wilson
1Lori Davis and Mary Beth Casselbury are triage nurses, and Sharon Wilson is a clinical nurse leader at the Lipson Cancer Institute in Rochester, N.Y.
Abstract:
Treatment with immune checkpoint inhibitors for cancer is associated with a high prevalence of multiple immune-related toxicities. Immune-related adverse events (irAEs) can occur anytime during treatment and up to 3 months after treatment. This article discusses checkpoint inhibitor therapy and describes the implementation of a patient education program focused on recognizing immunotherapy irAEs and their toxicities.
More Related Videos
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
09:01Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Related Concept Videos
Tumor Immunotherapy
Endocarditis IV: Nursing Management
Myocarditis III: Medical Management
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Myocarditis IV: Nursing Management
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...